NCT02934217

Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 868 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Infarct size is a major determinant of vital prognosis after AMI. We recently reported that cyclosporine A, when administered immediately prior to PCI reperfusion, can significantly reduce infarct size in STEMI patients. The CIRCUS study aimed at determining the impact of cyclosporine on the combined incidence of (death, hospitalization for heart failure, LV remodelling) at one year after AMI. However, many patients may display increased adverse LV remodelling beyond year 1 and develop heart failure thereafter. The present CIRCUS II trial aims at examining the 3-year clinical outcome of all patients recruited in the CIRCUS study.

Conditions

• ST Elevation Acute Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Injection of Cyclosporin	one single intravenous bolus injection of 2.5 mg/Kg
DRUG	Placebo	One single intravenous bolus injection of Placebo
PROCEDURE	Echocardiography	3 years after AMI

Timeline

• Start date: 2014-03-01
• Primary completion: 2017-06-28
• Completion: 2017-06-28
• First posted: 2016-10-14
• Last updated: 2018-05-22

Locations

1 site across 1 country: France